ArticleFrontiers in veterinary science2025
Redox status of biomarkers in serum of dogs with hypothyroidism and its treatment with levothyroxine sodium.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Information regarding canine hypothyroidism in China remains limited, particularly regarding the redox status of affected dogs. Therefore, the objective of this study was to evaluate the redox status of dogs with hypothyroidism and observe how it changed after levothyroxine replacement therapy. A total of 10 healthy dogs (control group) and 10 dogs with hypothyroidism (treatment group) from China Agricultural University Veterinary Teaching Hospital were included in the study. The redox status was assessed in all 20 dogs. Thyroid profiles such as thyroxine (T4), free thyroxine (fT4), and thyroid-stimulating hormone (TSH) and biomarkers of oxidative stress, including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-px), and malondialdehyde (MDA), were assessed on day 0 in all dogs and on days 14 and 45 post-levothyroxine sodium treatment in dogs with hypothyroidism. Dogs with hypothyroidism had decreased levels of serum T4 and fT4 and increased levels of serum TSH. Based on SOD, CAT, GSH-px, and MDA, dogs with hypothyroidism had oxidative stress. Following 45-day treatment with levothyroxine sodium (0.02 mg/kg orally twice daily), antioxidant parameters improved progressively: SOD increased from 60.2 to 76.7 U/mL (Day 0-14) and further to 83.3 U/mL (Day 45); CAT from 105.9 to 115.5 mU/mL (Day 0-14) reaching 132.9 mU/mL (Day 45); GSH-Px from 10.2 to 8.4 U/mL (Day 0-14) then 9.7 U/mL (Day 45), while MDA decreased from 8.2→6.8→4.4 μmol/L correspondingly. In conclusion, increased serum TSH and MDA concentrations, in addition to decreased serum T4 and fT4 concentrations and decreased SOD and CAT activities, indicated that there was oxidative stress in dogs with hypothyroidism. However, there were significant improvements in the redox status of biomarkers in the serum of dogs with hypothyroidism after treatment with levothyroxine sodium (0.02 mg/kg twice daily) for 45 days.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.